AMHR2

Across TCGA pan-cancer cohorts, AMHR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AMHR2 data layer compared with 21 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AMHR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AMHR2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where AMHR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.480	1.000	.005	31	view →
LUAD	OS	Median	II,III,IV	0.890	1.000	.015	9	view →
CCRCC	OS	Median	II,III,IV	0.030	0.764	.045	6	view →
GBM	DFS	Median	All	0.543	0.261	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AMHR2–HNSC (OS)

Open the HNSC breakdown →